These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 25348515)
21. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231 [TBL] [Abstract][Full Text] [Related]
22. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019 [TBL] [Abstract][Full Text] [Related]
24. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891 [TBL] [Abstract][Full Text] [Related]
25. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562 [TBL] [Abstract][Full Text] [Related]
26. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324 [TBL] [Abstract][Full Text] [Related]
27. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer. Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257 [TBL] [Abstract][Full Text] [Related]
28. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Sempere LF; Gunn JR; Korc M Cancer Biol Ther; 2011 Aug; 12(3):198-207. PubMed ID: 21613822 [TBL] [Abstract][Full Text] [Related]
30. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Ng SS; Tsao MS; Nicklee T; Hedley DW Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110 [TBL] [Abstract][Full Text] [Related]
31. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation. Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000 [TBL] [Abstract][Full Text] [Related]
32. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Park R; Al-Jumayli M; Miller K; Saeed A; Saeed A Cancer Treat Res Commun; 2021; 27():100342. PubMed ID: 33611092 [TBL] [Abstract][Full Text] [Related]
34. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921 [TBL] [Abstract][Full Text] [Related]
35. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261 [TBL] [Abstract][Full Text] [Related]
36. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Blasco MT; Navas C; Martín-Serrano G; Graña-Castro O; Lechuga CG; Martín-Díaz L; Djurec M; Li J; Morales-Cacho L; Esteban-Burgos L; Perales-Patón J; Bousquet-Mur E; Castellano E; Jacob HKC; Cabras L; Musteanu M; Drosten M; Ortega S; Mulero F; Sainz B; Dusetti N; Iovanna J; Sánchez-Bueno F; Hidalgo M; Khiabanian H; Rabadán R; Al-Shahrour F; Guerra C; Barbacid M Cancer Cell; 2019 Apr; 35(4):573-587.e6. PubMed ID: 30975481 [TBL] [Abstract][Full Text] [Related]
37. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Xiong G; Huang H; Feng M; Yang G; Zheng S; You L; Zheng L; Hu Y; Zhang T; Zhao Y J Exp Clin Cancer Res; 2018 Apr; 37(1):76. PubMed ID: 29615098 [TBL] [Abstract][Full Text] [Related]
38. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation. Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778 [TBL] [Abstract][Full Text] [Related]
39. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372 [TBL] [Abstract][Full Text] [Related]
40. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]